Drugs / norethisterone enantate

Trials 2

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02170038 Jun → Dec 2014 — Bayer Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02905890 Oct 2017 → Dec 2019 HIV infectious disease, bacterial vaginosis London School of Hygiene and Tropical Medicine Completed No outcome recorded
Comparator or background therapy1 trial
— NCT02404038 Comparator Jul 2015 → Jul 2017 HIV infectious disease Desmond Tutu HIV Centre Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as norethisterone enantate “Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.” NCT02170038 ↗
2

“Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).” NCT02404038 ↗

NCT02905890 ↗

Known as 17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one “Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).” NCT02404038 ↗
Known as Net-En “injectable norethisterone enanthate (Net-En), an etonorgesterol/ethinyl estradiol vaginal ring (NuvaRing), or oral contraceptives in the UChoose trial (NCT02404038) at baseline...” PMID 35348351 ↗ Mar 2022
Known as norethisterone enanthate “injectable norethisterone enanthate (Net-En), an etonorgesterol/ethinyl estradiol vaginal ring (NuvaRing), or oral contraceptives in the UChoose trial (NCT02404038) at baseline...” PMID 35348351 ↗ Mar 2022
Known as Noristerat “Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.” NCT02170038 ↗
Route Intramuscular “solution for intramuscular injection given every 8 weeks” NCT02905890 ↗